-Outlook Bhopal: India should continue with non-GMO (genetically modified) soybean in the larger interest of farmers and environment, experts said here today. "Non-GMO soya is the pride of India. Value added soy products including soybean meal are fetching premium price in the international market for being authentic non-GMO soy products. It is a win-win situation for all stakeholders in the value chain," Ruchi Soya Industries founder and MD Dinesh Shahra told reporters...

-The Times of India BHUBANESWAR: With high price of potato continuing to hit consumers hard, the state government has started taking several initiatives to tackle the crisis and increase production. A meeting, chaired by chief secretary G C Pati on Wednesday, chalked out strategies to create a buffer stock of 4 lakh quintal of potato to meet crisis situation. He attributed high price of potato to short supply from West Bengal. Potato is...

-The Hindu Business Line Now that the gains from the first round have petered out, we need to embrace biotech to boost farm productivity As India seeks to ignite the next agrarian revolution, it must try and absorb some of the lessons of the Green Revolution. Currently, agricultural productivity and growth vary from State to State, resulting in regional disparities. Through targeted policymaking, investment in rural infrastructure and research, and ongoing support...

-The Indian Express Rajkot/ Nagpur: For Kanaksinh Jadeja, Arvind Bhoyar and Rubhash Jakhar, cotton symbolised hope and a reason to believe there was still a future in agriculture. All three farmers - from Panchiyavadar in Gondal taluka of Rajkot (Gujarat), Ashi in Warora tehsil of Chandrapur (Maharashtra) and Patrewala in Fazilka (Punjab) respectively - made decent money over the last 10 years by growing cotton. They were helped by two factors. The first...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...